Matthew A Silva

Summary

Affiliation: Massachusetts College of Pharmacy and Health Sciences
Country: USA

Publications

  1. ncbi Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
    M A Silva
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA 01608, USA
    J Clin Pharm Ther 29:497-510. 2004
  2. ncbi Statin-related adverse events: a meta-analysis
    Matthew A Silva
    Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts 01608, USA
    Clin Ther 28:26-35. 2006
  3. ncbi Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Matthew A Silva
    Massachusetts College of Pharmacy and Health Sciences, Department of Pharmacy Practice, 19 Foster Street, Worcester, MA 01608, USA
    Vasc Health Risk Manag 2:39-48. 2006
  4. ncbi HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein
    Kristine Y Chan
    St. Luke's Medical Center, Milwaukee, WI, USA
    Am J Health Syst Pharm 61:1676-81. 2004

Collaborators

Detail Information

Publications4

  1. ncbi Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
    M A Silva
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA 01608, USA
    J Clin Pharm Ther 29:497-510. 2004
    ....
  2. ncbi Statin-related adverse events: a meta-analysis
    Matthew A Silva
    Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts 01608, USA
    Clin Ther 28:26-35. 2006
    ..The absolute frequencies of adverse events (AEs) between statins and placebo are very low in clinical trials, making clinical interpretation and application difficult...
  3. ncbi Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Matthew A Silva
    Massachusetts College of Pharmacy and Health Sciences, Department of Pharmacy Practice, 19 Foster Street, Worcester, MA 01608, USA
    Vasc Health Risk Manag 2:39-48. 2006
    ..These new data will impact emerging guidelines and updates are currently in progress...
  4. ncbi HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein
    Kristine Y Chan
    St. Luke's Medical Center, Milwaukee, WI, USA
    Am J Health Syst Pharm 61:1676-81. 2004
    ..CONCLUSION: The lowering of elevated CRP levels by statins may reduce the risk of coronary events independently of the effect of statins on lipid levels...